Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301

Abstract

Lazertinib demonstrated significant efficacy improvement compared with gefitinib in the first-line treatment of <i>EGFR</i>-mutated advanced NSCLC, with a manageable safety profile.